Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Phase 1 Completed 6 enrolled Biocad

NaSingle-groupOpen-labelTreatment

Summary

A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of Oral BCD-115 (JSC BIOCAD, Russia) in Combination with Endocrine Therapy in Women with ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Timeline

Start: 2016-11
Primary completion: 2018-03
Completion: 2018-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SENEXIN B	Small molecule	—	Oral

Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Summary

Timeline

Drugs

Indications